对于正静性低血压的药理干预:系统性审查
Anushka Verma1, Eiman Saraya2, Mehjabin S Haque3
1Internal Medicine, Smt. Nathiba Hargovandas Lakhmichand (NHL) Municipal Medical College, Ahmedabad, IND.
Cureus
|September 15, 2025
概括
药物治疗有效地控制静止性低血压 (OH),这种情况会导致站立时血压下降. 德罗西多巴和米多德林是推的第一线疗法,而其他疗法则显示出适度的益处,但个性化的方法至关重要.
科学领域:
- 心脏病学 心脏病学
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 静止性低血压 (OH) 是一种常见的,使人虚弱的疾病,影响老年人和患有神经退行性疾病的人.
- OH显著损害生活质量,增加跌倒,昏迷,发病率和死亡率的风险.
研究的目的:
- 系统地审查对静止性低血压的药理疗法的疗效和安全性.
- 评估用于OH管理的各种药物类别的证据.
主要方法:
- 系统性审查遵循PRISMA 2020指南,分析了25个RCT和NRCT.
- 使用Cochrane ROB 2,JBI检查表和NOS进行质量评估.
- 用GRADE框架评估的证据确定性.
主要成果:
- 经FDA批准的德洛克西多巴和米多德林显示出作为一线OH治疗的持续有效性.
- 亚托莫克西丁和弗鲁德科尔提松显示中度有效性; 皮里多斯蒂格提供辅助益处.
- 奥克特雷奥提德显示了耐火性OH的潜力,但证据有限. 常见的不良反应包括卧底高血压和头.
结论:
- 药理干预措施在治疗正静性低血压症状方面具有显著的益处.
- 个性化治疗策略至关重要,以平衡疗效和耐受性,尽量减少不良影响.
- 需要进一步进行比较和长期研究,以优化OH的治疗方法.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
942
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
942
Hypertension IV: Drug Therapy and Lifestyle Modifications
624
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
624
Antihypertensive Drugs: Vasodilators
2.0K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.0K
Alterations in Blood Pressure
2.1K
Alterations in blood pressure, such as hypertension (high blood pressure) and hypotension (low blood pressure), significantly affect human health. Understanding these conditions' classifications, causes, and symptoms is essential for effective management and treatment.
Hypertension (High blood pressure)
Hypertension occurs when blood pressure readings consistently exceed the normal range. It is diagnosed when systolic blood pressure (the top number, indicating pressure while the heart...
Hypertension (High blood pressure)
Hypertension occurs when blood pressure readings consistently exceed the normal range. It is diagnosed when systolic blood pressure (the top number, indicating pressure while the heart...
2.1K
Heart Failure V: Medical Management
223
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
567
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
567


